What Did the Research Discover? A systematic review and meta-analysis examined how well semaglutide helps people lose weight if they are obese or overweight but do not have diabetes. Researchers analyzed data from eight clinical trials with 4,567 participants, comparing semaglutide to a placebo. The results showed that semaglutide led to significant weight loss: On...
For Immediate Release: April 10, 2025 Today, the U.S. Food and Drug Administration is taking a groundbreaking step to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods. The new approach is designed to improve drug safety and accelerate the evaluation...
What did the research discover? This study examined whether low vitamin D levels before chemotherapy increase the risk of developing chemotherapy-induced peripheral neuropathy (CIPN) in patients receiving paclitaxel for early-stage breast cancer. CIPN is a common and painful side effect of chemotherapy that affects nerves, leading to tingling, numbness, and pain,...
What did the research discover? A review of the 2024 Alzheimer's disease (AD) drug pipeline found 164 clinical trials testing 127 drugs, a decline from 187 trials and 141 drugs in 2023. The pipeline consists of: 48 trials in Phase 3 (testing 32 drugs) 90 trials in Phase 2 (testing 81 drugs) 26 trials in Phase 1 (testing 25 drugs) Most drugs in the pipeline aim to...
What did the research discover? This study investigated how zinc oxide (ZnO) affects the safety and effectiveness of sunscreen ingredients when exposed to UV light. Sunscreens are generally tested based on individual ingredients, but their stability and safety depend on how these ingredients interact in a formulation. Researchers tested five common small-molecule...
For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s...